Phe-Gly Mimetics
p-methylbenzhydrylamine; NMM, N-methylmorpholine; Pen,
J ournal of Medicinal Chemistry, 1999, Vol. 42, No. 21 4341
(30) Thompson, S. K.; Eppley, A. M.; Frazee, J . S.; Darcy, M. G.; Lum,
R. T.; Tomaszek, T. A., J r.; Ivanoff, L. A.; Morris, J . F.; Sternberg,
E. J .; Lambert, D. M.; Fernandez, A. V.; Petteway, S. R., J r.;
Meek, T. D.; Metcalf, B. W.; Gleason, J . G. Synthesis and
antiviral activity of a novel class of HIV-1 protease inhibitors
containing a heterocyclic P1′-P2′ amide bond isostere. Bioorg.
Med. Chem. Lett. 1994, 4, 2441-2446.
(31) Pernow, B. Substance P. Pharmacol. Rev. 1983, 35, 85-141.
(32) Regoli, D.; Boudon, A.; Fauche`re, J .-L. Receptors and antagonists
for substance P and related peptides. Pharmacol. Rev. 1994, 46,
551-599.
(33) De Castiglione, R. Structure-activity relationships in dermor-
phin-like peptides. In Highlights in Receptor Chemistry; Mel-
chiorri, C., Giannella, M., Eds.; Elsevier Sci: Amsterdam, 1984;
pp 149-168.
(34) De Castiglione, R.; Rossi, A. C. Structure-activity relationships
of dermorphin synthetic analogues. Peptides 1985, 6 (Suppl. 3),
117-125.
(35) Melchiorri, P.; Negri, L. The Dermorphin Peptide Family. Gen.
Pharmacol. 1996, 27, 1099-1107.
(36) Cascieri, M. A.; Huang, R.-R. C.; Fong, T. M.; Cheung, A. H.;
Sadowski, S.; Ber, E.; Strader, C. D. Determination of the amino
acid residues in substance P conferring selectivity and specificity
for the rat neurokinin receptors. Mol. Pharmacol. 1992, 41,
1096-1099.
(37) Salvadori, S.; Sarto, G.; Tomatis, R. Synthesis and pharmaco-
logical activity of dermorphin and its N-terminal sequences. Int.
J . Pept. Protein Res. 1982, 19, 536-542.
(38) Pseudopeptides are defined as modified peptides containing
sequences that are not peptidergic. Pseudopeptides can be
obtained by, e.g., isosteric replacement of peptide bonds or
replacement of larger fragments in the peptide with nonpeptidic
structures.
(39) Cox, M. T.; Gormley, J . J .; Hayward, C. F.; Petter, N. N.
Incorporation of trans-olefinic dipeptide isosteres into enkephalin
and substance P analogues. J . Chem. Soc., Chem. Commun.
1980, 800-802.
(40) Allmendinger, T.; Felder, E.; Hungerbu¨hler, E. Fluoroolefin
dipeptide isosteres - II. Enantioselective synthesis of both
antipodes of the Phe-Gly dipeptide mimic. Tetrahedron Lett.
1990, 31, 7301-7304.
(41) Ewenson, A.; Laufer, R.; Chorev, M.; Selinger, Z.; Gilon, C.
Ketomethylene pseudopeptide analogues of substance P: Syn-
thesis and biological activity. J . Med. Chem. 1986, 29, 295-299.
(42) Chorev, M.; Rubini, E.; Gilon, C.; Wormser, U.; Selinger, Z.
Synthesis of partially modified retro-inverso substance P ana-
logues and their biological activity. J . Med. Chem. 1983, 26,
129-135.
(43) Roubini, E.; Laufer, R.; Gilon, C.; Selinger, Z.; Roques, B. P.;
Chorev, M. Pseudopeptide analogues of substance P and leucine
enkephalinamide containing the ψ[CH2O] modification: Syn-
thesis and biological activity. J . Med. Chem. 1991, 34, 2430-
2438.
penicillamine; PyBrOP, bromotrispyrrolidinophosphonium hexa-
fluorophosphate; SP, substance P; SPL, Sybyl programming
language; SPPS, solid-phase peptide synthesis; TBAF, tetra-
butylammonium fluoride; TBTU, O-(benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium tetrafluoroborate; TFMSA, trifluoromethane-
sulfonic acid; TMSI, iodotrimethylsilane; Tos, p-toluenesulfonyl.
(2) Spatola, A. F.; Darlak, K. Amide bond surrogates: Pseudopep-
tides and macrocycles. Tetrahedron 1988, 44, 821-833.
(3) Hruby, V. J .; Al-Obeidi, F.; Kazmierski, W. Emerging approaches
in the molecular design of receptor-selective peptide ligands:
Conformational, topographical and dynamic considerations.
Biochem. J . 1990, 268, 249-262.
(4) Ho¨lzemann, G. Peptide conformation mimetics. Kontakte (Darm-
stadt) 1991, 3-12 (Part 1) and 55-63 (Part 2).
(5) Chorev, M.; Goodman, M. A dozen years of retro-inverso pepti-
domimetics. Acc. Chem. Res. 1993, 26, 266-273.
(6) Freidinger, R. M. Toward peptide receptor ligand drugs: Progress
on nonpeptides. Prog. Drug. Res. 1993, 40, 33-98.
(7) Giannis, A.; Kolter, T. Peptidomimetics for receptor ligands -
discovery, development, and medicinal perspectives. Angew.
Chem., Int. Ed. Engl. 1993, 32, 1244-1267.
(8) Olson, G. L.; Bolin, D. R.; Bonner, M. P.; Bo¨s, M.; Cook, C. M.;
Fry, D. C.; Graves, B. J .; Hatada, M.; Hill, D. E.; Kahn, M.;
Madison, V. S.; Rusiecki, V. K.; Sarabu, R.; Sepinwall, J .;
Vincent, G. P.; Voss, M. E. Concepts and Progress in the
Development of Peptide Mimetics. J . Med. Chem. 1993, 36,
3039-3049.
(9) Adang, A. E. P.; Hermkens, P. H. H.; Linders, J . T. M.;
Ottenheijm, H. C. J .; Van Staveren, C. J . Case histories of
peptidomimetics: progression from peptides to drugs. Recl. Trav.
Chim. Pays-Bas 1994, 113, 63-78.
(10) Gante, J . Peptidomimetics - tailored enzyme inhibitors. Angew.
Chem., Int. Ed. Engl. 1994, 33, 1699-1720.
(11) Liskamp, R. M. J . Conformationally restricted amino acids and
dipeptides, (non)peptidomimetics and secondary structure mi-
metics. Recl. Trav. Chim. Pays-Bas 1994, 113, 1-19.
(12) Nowick, J . S.; Smith, E. S.; Pairish, M. Artificial â-sheets. Chem.
Soc. Rev. 1996, 25, 401-415.
(13) Hanessian, S.; McNaughton-Smith, G.; Lombart, H.-G.; Lubell,
W. D. Design and synthesis of conformationally constrained
amino acids as versatile scaffolds and peptide mimetics. Tetra-
hedron 1997, 53, 12789-12854.
(14) J enmalm, A.; Luthman, K.; Lindeberg, G.; Nyberg, F.; Terenius,
L.; Hacksell, U. Novel peptidomimetics: Inhibitors of substance
P endopeptidase. Bioorg. Med. Chem. Lett. 1992, 2, 1693-1698.
(15) Li, Y.-L.; Luthman, K.; Hacksell, U. Novel L-Phe-Gly mimetics.
Tetrahedron Lett. 1992, 33, 4487-4490.
(16) Borg, S.; Estenne-Bouhtou, G.; Luthman, K.; Cso¨regh, I.; Hes-
selink, W.; Hacksell, U. Synthesis of 1,2,4-oxadiazole-, 1,3,4-
oxadiazole-, and 1,2,4-triazole-derived dipeptidomimetics. J . Org.
Chem. 1995, 60, 3112-3120.
(44) Wilkes, B. C.; Schiller, P. W. Conformation-activity relationship
of cyclic dermorphin analogues. Biopolymers 1990, 29, 89-95.
(45) Shenderovich, M. D.; Nikiforovich, G. V.; Golbraikh, A. A.
Conformational features responsible for the binding of cyclic
analogues of enkephalin to opioid receptors. III. Probable binding
conformations of µ-agonists with phenylalanine in position 3.
Int. J . Pept. Protein Res. 1991, 37, 241-251.
(46) Tourwe´, D.; Verschueren, K.; van Binst, G.; Davis, P.; Porreca,
D.; Hruby, V. J . Demorphin sequence with high δ-affinity by
fixing the Phe side chain to trans at ø1 Bioorg. Med. Chem. Lett.
1992, 2, 1305-1308.
(47) Salvadori, S.; Marastoni, M.; Balboni, G.; Sarto, G.; Tomatis, R.
Synthesis and opioid activity of partial retro-inverso analogues
of dermorphin. Int. J . Pept. Protein Res. 1985, 25, 526-533.
(48) Marastoni, M.; Balboni, G.; Salvadori, S.; Sarto, G. P.; Tomatis,
R. Structure-activity relationships of dermorphin tetrapeptides
carrying a ketomethylene linkage. Arzneim.-Forsch./ Drug Res.
1985, 35 (II), 1630-1632.
(49) J aspers, H.; Tourwe´, D.; van Binst, G.; Pepermans, H.; Borea,
P.; Ucelli, L.; Salvadori, S. Dermorphin tetra- and heptapeptide
analogues containing a [3,4] amide bond replacement by a
carbon-carbon double and single bond. Int. J . Pept. Protein Res.
1992, 39, 315-321.
(50) Darlak, K.; Grzonka, Z.; Spatola, A. F.; Benovitz, D. E.; Burks,
T. F.; Wire, W. S. Synthesis, biological activities, and enzymatic
stabilities of dermorphin pseudopeptides. Peptides 1988 1989,
634-636.
(51) Weiner, S. J .; Kollman, P. A.; Nguyen, D. T.; Case, D. A. An all
atom force field for simulations of proteins and nucleic acids. J .
Comput. Chem. 1986, 7, 230-245.
(52) Mohamadi, F.; Richards, N. G. J .; Guida, W. C.; Liskamp, R.;
Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W.
C. MacroModel - An integrated software system for modeling
organic and bioorganic molecules using molecular mechanics.
J . Comput. Chem. 1990, 11, 440-467.
(17) Behr, L. C. 1,3,4-Oxadiazoles. In The Chemistry of Heterocyclic
Compounds; Weissberger, A., Ed.; Wiley: New York, 1962; pp
263-282.
(18) Nesynov, E. P.; Grekov, A. P. The chemistry of 1,3,4-oxadiazole
derivatives. Russ. Chem. Rev. 1964, 33, 508-515.
(19) Hetzheim, A.; Mo¨ckel, K. Recent advances in 1,3,4-oxadiazole
chemistry. In Advances in Heterocyclic Chemistry; Katritzky, A.
R., Boulton, A. J ., Eds.; Academic Press: New York, 1966; pp
183-224.
(20) Hill, J . 1,3,4-Oxadiazoles. In Comprehensive Heterocyclic Chem-
istry; Potts, K. T., Ed.; Pergamon Press: Oxford, 1984; pp 427-
446.
(21) Behr, L. C. 1,2,4-Oxadiazoles. In The Chemistry of Heterocyclic
Compounds; Weissberger, A., Ed.; Wiley: New York, 1962; pp
245-262.
(22) Eloy, F. A review of the chemistry of 1,2,4-oxadiazoles. Fortschr.
Chem. Forsch. 1965, 4, pp 807-876.
(23) Clapp, L. B. 1,2,4-Oxadiazoles. Adv. Heterocycl. Chem. 1976, 20,
65-116.
(24) Clapp, L. B. 1,2,3- and 1,2,4-Oxadiazoles. In Comprehensive
Heterocyclic Chemistry; Potts, K. T., Ed.; Pergamon Press:
Oxford, 1984; pp 365-392.
(25) Potts, K. T. The chemistry of 1,2,4-triazoles. Chem. Rev. 1961,
61, 87-127.
(26) Temple, C., J r. 1,2,4-Triazoles; J ohn Wiley & Sons: New York,
1981; Vol 37.
(27) Polya, J . B. 1,2,4-Triazoles. In Comprehensive Heterocyclic
Chemistry; Potts, K. T., Ed.; Pergamon Press: Oxford, 1984; pp
733-790.
(28) See ref 16 and refs 6-8 therein.
(29) Burrell, G.; Evans, J . M.; Hadley, M. S.; Hicks, F.; Stemp, G.
Benzopyran potassium channel activators related to cromakalim
- Heterocyclic amide replacement at position 4. Bioorg. Med.
Chem. Lett. 1994, 4, 1285-1290.